Germantown, MD, 6th February 2012 – XCELERON, a leader in accelerating drug development using ultra-sensitive bioanalytical analyses, today announced that existing investors Albion Ventures and Solon Ventures have invested $2.4MM to locate all of the company’s business in its custom-built facility in Germantown, MD which is expected to be fully operational by 31st March 2012. 


Xceleron is relocating senior analytical staff to Germantown from York, hiring new staff in Maryland and retaining a strong study design and project management presence in the UK.  The Germantown facility was opened for business in 2008 and has conducted a range of customer studies including absolute bioavailability, metabolism and general pharmacokinetic investigations.  12,000 samples have been analyzed on site for a growing client base of pharmaceutical and biotech companies.


Xceleron intends to augment its analytical capability in Germantown with the latest in highly sensitive LC-MS/MS technology.  This addition will create the first laboratory of its kind in which all forms of microtracer and microdose investigations can be conducted in one custom-built facility.


Stuart Best, Vice President Analytical Operations added: “The combined ruggedness of AMS and the specificity of the most sensitive LC-MS/MS will enable a highly cost-effective and safe bridge from discovery to the clinic.”


Xceleron CEO Michael Butler commented: “Our customers told us that they want access to the best analytical platforms in translational science.  We are providing that access with the most experienced team in the business and in one highly efficient and purpose built location.  This is a first-of-a-kind combination from Xceleron that we believe will add to our customers’ drive for Phase 2-readiness”





About Xceleron

Founded in 1997 in York, UK, Xceleron provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials.  


Xceleron pioneered the use of human microtracer and AMS and has unmatched robust processes and knowledge of experimental design. There are currently 6 drugs on the market that have used Xceleron AMS data in filing, and another 3 in late stages of development. In 2008, the company opened its US facility in Maryland. For company information, visit Xceleron at



Media Contact:

Michael Butler

Tel  +1 240 306 2050

Cell +1 240 477 3895


For further information or to arrange an interview contact:

Deborah Cockerill

Cell +44 (0)7930 317729


Got an innovation you need bringing to life?

We’d love to hear from you! Head to our contact page to start a conversation.

Photo of Deborah Cockerill